Home / Resource Library / Novel biologic therapies in relapsed or refractory diffuse large B cell lymphoma: CAR-T is not the only answer

Novel biologic therapies in relapsed or refractory diffuse large B cell lymphoma: CAR-T is not the only answer

Article reviews novel therapies for the treatment of relapsed DLBCL.